SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|
| Trimbow | 87,9,5 µg,µg,µg | Pressurised inhalation, solution · Inhalation use | 1 Aluminum Can | SAR 236.80 | NCE · Prescription | CHIESI FARMACEUTICIS | Valid |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|
| TRIMBOW | 0.086MG/INH;0.0049MG/INH;0.0106MG/INH; 0.172MG/INH;0.0049MG/INH;0.0106MG/INH | aerosol, metered · inhalation | CHIESI | Prescription | 14 May 2026 |
EMA European Union — centrally authorised medicines
Trimbow Chiesi Farmaceutici S.p.A. · Authorised · authorised 17 Jul 2017 · ATC R03AL09
Therapeutic indication (EMA)
Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. COPDMaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1). AsthmaMaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.
Trydonis Chiesi Farmaceutici S.p.A. · Authorised · authorised 26 Apr 2018 · ATC R03AL09
Therapeutic indication (EMA)
Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1).
Therapeutic indication (EMA)
Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1).
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|
| TRIMBOW | 02557592 | 6 MCG / ACT; 100 MCG / ACT; 10 MCG / ACT | AEROSOL (METERED-DOSE) · INHALATION | CHIESI FARMACEUTICI S.P.A. |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.